Search results

Collaboration between Clinerion and Citeline leads to more informed decisions for clinical researchers, grounded in real-world evidence.

Santhera Pharmaceuticals (SIX: SANN) announces results from the SYROS study demonstrating that long-term treatment with idebenone consistently reduced the rate of respiratory function loss in patients with Duchenne muscular dystrophy (DMD) for up to 6 years in a real-world setting. This long-term data further supports the potential for idebenone to modify the course of respiratory function de

Ten finalists have been chosen for the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology The Award recognizes Patient Entrepreneurs’ innovations for cancer and cancer supportive care using therapeutics, diagnostics, medical devices or healthcare IT tools

BioTarget is a global biotech competition aimed at identifying and supporting those working on new molecules for cancer therapy. Research groups with entrepreneurial ambitions and young biotech companies can submit a proposal by March 29th. The shortlisted candidates will be invited for a pitch event in London, UK, and the three winners will receive free experimentation worth up to $100,000 in Eur

Combination of antibody drug conjugate and checkpoint inhibitor being evaluated for treatment of relapsed or refractory diffuse large B-cell, mantle cell and follicular lymphomas

With 30 years of cumulative experience at Novartis and Janssen, Prof. Wolf strengthens InSphero leadership team and augments 3D model and organ-on-a-chip R&D.

CARB-X to fund the preclinical development and Phase I clinical trial of a novel OMPTA candidate.

Early proof-of-concept studies demonstrate versatility of scalable microfluidic platform for 3D microtissue-based multi-organ models.

Decision follows Independent Data Monitoring Committee analysis The Alzheimer’s Prevention Initiative (API) study of crenezumab in familial Alzheimer’s disease continues The Phase II anti-tau TAURIEL trial led by Roche in partnership with AC Immune continues 

Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumor

Swiss Diagnostic Startup Closes Seed Financing Round of CHF 3 Million Within the First Year

Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today that it has signed additional commercial license agreements (CLAs) with Agenus Inc., (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, and adoptive cell therapies.1 Under the new CLAs, Agenus will leverage Selexi

21% objective response rate with six confirmed partial responses from 29 evaluable patients 83% disease control rate Safety profile and tolerability of continuous dosing schedule confirmed

Highly Complementary Portfolios with Leading Franchises in Oncology, Immunology and Inflammation and Cardiovascular Disease Significantly Expands Phase III Assets with Six Expected Near-Term Product Launches, Representing Greater Than $15 Billion in Revenue Potential Registrational Trial Opportunities and Early-Stage Pipeline Position Combined Company for Sustained Leadership Underpinned by Cuttin

Potential for new immune-oncology therapy using an antibody drug conjugate that targets regulatory T cells

Prof. Mario Sznol, Yale Cancer Center, Prof. David Hong, MD Anderson Cancer Center to join CAB Company advances lead compound ND021 to clinic

Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin® Molecule, in Combination with Amgen’s Oncology Assets, Including BiTE® Molecules Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products

Financing round led by FC Capital, Shanghai; PPF / Sotio, Prague; ETP Ventures, Boston & Beijing and significant investments by existing and new private investors  Funds will be used to complete the ongoing Phase I clinical trial and advance R&D pipeline First patient data confirm expectations on pharmacokinetics, safety and efficacy Melissa Kay Epstein elected to Cellestia’s Board of D

AC Immune to draw on WuXi Biologics' expertise in manufacturing innovative New Biological Entities against CNS disorders including proprietary WuXiUP continuous manufacturing platform that can significantly reduce cost of biologics AC Immune to gain access to WuXi Biologics' proprietary discovery platforms including the WuXiBody(TM) Platform used for the generation of bispecific antibodies WuXi Bi

Selexis SA and Teneobio, Inc. announced today that they have entered into a second services agreement to expand Teneobio's oncology pipeline of Human Heavy-Chain Antibodies (UniAbs™), a new class of multi-specific biologics. Under the agreement, Teneobio will utilize Selexis' proprietary SUREtechnology Platform™ to develop research cell banks (RCBs) for three additional preclinical candidates

Success criteria met: Bet v 1 COP-virosomes showed no IgE induction, favorable TH1 response and were well tolerated in mice study Anergis has time limited exclusive option to license Mymetics’ virosome technology in the field of allergies

Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential near-term development milestones, up to approximately CHF1.7 billion in other potential development, regulatory and commerci

MetrioPharm closes Private Equity Financing Round D Funds to be used for ongoing Phase II study and a Phase IIa study in an additional indication

Santhera Pharmaceuticals (SIX: SANN) announces that a vast majority of shareholders approved the ordinary capital increase at today's Extraordinary General Meeting (EGM). Participating shareholders represented a total of 2'953'737 shares or 39% of the share capital.

The proposed study is intended to support the global registration of balixafortide. Polyphor expects to enroll the first patient in the second quarter of 2019.